Ready to Give Patients a Better Way Forward?
The Vibrant System™ is the first-in-class, FDA-cleared capsule therapy for chronic idiopathic constipation. Clinically proven to deliver effective relief from constipation* with fewer side effects than the most common drugs & laxatives.
*Chronic idiopathic constipation
Explore Vibrant in the Clinical Literature
“I feel like a normal human being again!”
Read her experience
“I love the fact that it’s not another drug. I’ve eaten handfuls of laxatives & drank every nasty liquid solution there is—without success… With Vibrant, I now have bowel movements 3—sometimes 4—times each week. My stomach is not as distended; I’ve lost at least 20 pounds, & I feel like a normal human being again.”
Individual results may vary.Vibrant Delivers Durable Efficacy with Exceptionally Low Diarrhea Rates in Adults with Constipation*
- Real-world outcomes from 1,722 adults treated across U.S. community practices
- Sustained improvement in bowel habits and stool form at 3 and 6 months
- Diarrhea in only 0.64% of patients, far below rates reported with commonly used pharmacologic options
New real-world evidence on the Vibrant System™ has been published in Clinical and Translational Gastroenterology, presenting outcomes from 1,722 adults treated across U.S. community practices.
Among patients who completed 3 or 6 months of therapy and used the electronic stool diary, treatment with Vibrant demonstrated consistent, clinically meaningful improvements:
- More than one additional CSBM per week on average (p<0.0001)
- Stool form improved from a mean of 2.9 at baseline to 4.1 during treatment
- Straining decreased by 45%, and average toileting time fell from ~33 minutes to ~15 minutes
These improvements were sustained at both 3- and 6-month follow-up.
Read the Full ArticleTolerability is where Vibrant clearly stands out. Diarrhea rates in this real-world cohort were markedly lower than those reported with commonly used pharmacologic options for CIC:
| Therapy | Mechanism | Reported diarrhea rate |
|---|---|---|
| Vibrant System™ (real-world) | Non-drug, mechanized colonic stimulation | 0.64% |
| Linaclotide | GC-C agonist | ≈ 15–20% in CIC trials |
| Plecanatide | GC-C agonist | ≈ 5–6% in CIC trials |
| Lubiprostone | Chloride channel (ClC-2) activator | ≈ 10–15% in CIC trials |
Approximate rates shown for adults with CIC based on published clinical trial data for pharmacologic agents and real-world observational data for Vibrant.
In the Vibrant real-world cohort, diarrhea occurred in only 0.64% of patients, with abdominal pain and bloating/distention each ≤~2%. For patients who have cycled through secretagogues or GC-C agonists due to tolerability concerns, these data highlight Vibrant as an effective, well-tolerated, drug-free option to consider earlier in the treatment journey.
*Chronic idiopathic constipation
People are frustrated with their current options.
Millions of people are suffering in silence, trying as many things as they can, but not making progress.
Over 60% say current treatments, which often cause diarrhea, are worse than the constipation itself.
Just 1.2% of those using the Vibrant capsule reported diarrhea.
A drug-free option can change the conversation.
Talk to a RepSee How Vibrant Fits Your Practice.
Learn how Vibrant® delivers drug-free, FDA-cleared relief for CIC with a 15-minute walkthrough. We’ll cover how it works, prescribing details, and answer any questions you have.
Prefer to talk now? Call 866-359-7532 (press 1 for VibrantConnect) or email service@vibrantgastro.com.
Prescribing the Vibrant System®
A first-in-class, FDA-cleared vibrating capsule for chronic idiopathic constipation in adults—drug-free, with no systemic side effects. Prescribing takes two simple steps.
The Vibrant System® is now dispensed by MedOptions Rx—same treatment, same care.
Select Vibrant in your EHR
60009-0189-8260009-0189-80Please include the patient’s ICD-10 diagnosis code(s)—e.g., K59.04—in the prescription notes, along with any previous use of prescribed constipation medications.
Select MedOptions Rx, Specialty Pharmacy
All prescriptions should be sent to MedOptions Rx, our specialty pharmacy partner.
- Phone
- 866-359-7532
- Fax
- 844-956-5987
- NPI
- 1699667147
- Address
- 450 E Devon Ave, Ste 170, Itasca, IL 60143
Dosing, Ordering & Support
The essentials are shown below—expand any section for the full detail.
Dosing & AdministrationOne capsule, by mouth, at bedtime—5 nights a week.
Take one capsule by mouth at bedtime, 5 nights per week. No bowel prep, fasting, or timing with meals is required.
20 capsules = a one-month supply. Refills as clinically appropriate.
Full Instructions for Use ↗Product Identifiers & Order TablesStarter Kit, refill, SIG, and GTIN information.
| Product | NDC | GTIN-14 | Dispense |
|---|---|---|---|
| Vibrant Starter Kit (new patients) | 60009-0189-82 | 860009189829 | 1 kit / 30 days |
| Vibrant Capsules (refill) | 60009-0189-80 | 860009189805 | 20 caps / 30 days |
SIG: Take once daily, up to 5×/week, at bedtime. Notes: include ICD-10 for CIC (e.g., K59.04) and prior treatment history.
Ordering for the VAReferral → secure e-fax → PO and refills for Veterans.
- Submit forms. For new patients, enter a Prosthetics consult for the Vibrant Starter Kit; complete the VA Referral Form and send it to your VA Pharmacy.
- Pharmacy review & e-fax. VA Pharmacy reviews and e-faxes MedOptions Rx at 844-956-5987.
- Payment. Issue PO to Vibrant Gastro, Inc.; MedOptions Rx e-invoices via Tungsten on Vibrant’s behalf. Credit card available on request.
- Refills. The pharmacy contacts the VA 3–4 business days before the next refill to confirm dispensing and payment.
- Fulfillment. Typical shipment 2–5 business days to the Veteran’s home or VA Pharmacy.
FSS Contract # 36F79725D0174 | UEI GDBXXGNGXH75 | CAGE 9TXD2
Who to ContactPress 1 for VibrantConnect; press 2 for MedOptions Rx.
VibrantConnect Team
Medical, clinical, product & technical support.
866-359-7532
MedOptions Rx
Prescriptions, transfers & refills.
Phone: 866-359-7532
Fax: 844-956-5987
NPI: 1699667147
Intended for U.S. healthcare professionals. The Vibrant System® is FDA-cleared for the treatment of chronic idiopathic constipation in adults. Please refer to the full Instructions for Use before prescribing. MedOptions Rx is an independent, licensed specialty pharmacy provider; prescription transfers are handled securely under HIPAA.
The Data, Organized for Fast Review.
Real-world outcomes, Phase 3 efficacy, safety information, and adverse-event rates—kept compact until you want the detail.
Long-Term, Real-World Evidence3- and 6-month outcomes from U.S. community practices
Long-Term, Real-World Evidence of Vibrating Capsule Treatment
Improved Bowel Frequency
Patients using Vibrant experienced a >1 additional complete spontaneous bowel movement per week compared with baseline over 3 and 6 months.
Enhanced Stool Consistency
Average BSFS scores improved from approximately 2.9 → 4.1, indicating softer, more normal stool form and easier passage.
Reduced Straining and Toileting Time
Patients reported less straining (2.9 → 1.6) and shorter time spent on the toilet (p<0.0001 for both parameters).
Well-Tolerated and Safe
Adverse events were rare—only 0.64% reported diarrhea, and no serious device-related adverse events occurred.
Phase 3 Randomized, Placebo-Controlled TrialPrimary CSBM response and secondary outcomes
Phase 3 Randomized, Placebo-Controlled Trial
In a double-blind, placebo-controlled Phase 3 trial in adults with chronic idiopathic constipation, Vibrant demonstrated significantly higher responder rates for complete spontaneous bowel movements and significant improvements in multiple secondary symptom and quality-of-life measures.2
Significant Improvement in Incremental Complete Spontaneous Bowel Movements (CSBMs)
- Vibrant Capsule led to one or more additional CSBMs per week in 39.3% of patients, compared with 22.1% in the placebo arm.2
- 22.7% of patients taking Vibrant achieved two or more additional CSBMs per week, compared with 11.4% taking placebo.2
Improvement in overall constipation symptoms: straining score
Improvement in overall constipation symptoms: stool consistency
Improvement in quality of life from baseline (PAC-QOL overall score)
Values shown represent adjusted mean change from baseline for secondary endpoints reported in the Phase 3 study.
Conclusions
Vibrant demonstrated significant improvement in stool frequency, other bowel and abdominal symptoms, and quality of life. The regimen established tolerability with no significant adverse events. Vibrant provides a novel, non-pharmacological, intraluminal therapy that is effective, safe, and well tolerated in patients with CIC.2
2 Rao SSC, Quigley EMM, Chey WD, Sharma A, Lembo A. Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation. Gastroenterology. 2023;164(7):1202–1210.
Safety, Contraindications & WarningsEssential safety information in one place
Safety
Potential adverse events associated with use of this device may include abdominal pain, abdominal distension, abdominal discomfort, vomiting, nausea, blood in stool, diarrhea, flatulence, and proctalgia. In rare cases, obstruction may occur.
Note that the safety and effectiveness of the Vibrant System for long-term use in the indicated population, i.e., for more than 8 weeks, has not been evaluated.
Contraindications
Vibrant should not be used if your patient:
- has a history of complicated/obstructive diverticular disease.
- has a history of intestinal or colonic obstruction, or suspected intestinal obstruction.
- currently has clinical evidence of significant gastroparesis.
- has a history of significant gastrointestinal disorder, including any form of inflammatory bowel disease or gastrointestinal malignancy (celiac disease is excepted if the subject has been treated and is in remission), and/or anal fissures and fistulas.
- has a history of Zenker's diverticulum, dysphagia, esophageal stricture, eosinophilic esophagitis, or achalasia.
- is pregnant or lactating.
Warnings
- The Vibrant Capsule is MR unsafe. The device has not been evaluated for safety and compatibility in the MR (magnetic resonance) environment. It has not been tested for heating, migration, or image artifact in the MR environment. If a patient requires an MRI, verify Capsule expulsion via abdominal X-ray before undergoing an MRI examination.
- The Capsule should be kept away from implants such as pacemakers, defibrillators, nerve stimulators, and other devices that could be affected by proximity to a DC (direct current) magnetic field.
- Vibrant Capsules must be stored in a safe place, out of the reach of children and/or infants.
- If a child has accidentally swallowed an unused Vibrant Capsule, he/she should be brought immediately to a hospital.
Adverse-Event RatesVibrant and placebo rates reported in the Phase 3 study
| Gastrointestinal disorder | Vibrant | Placebo |
|---|---|---|
| Total | 6.13% | 9.40% |
| Abdominal pain | 0.61% | 4.03% |
| Vomiting | 1.23% | 0.67% |
| Nausea | 1.84% | 0.67% |
| Abdominal distension | 0.61% | 1.34% |
| Diarrhea | 1.23% | — |
Let’s talk through where Vibrant fits.
References
- Rao SSC, Quigley EMM, Chey WD, Sharma A, Lembo A. Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation. Gastroenterology. 2023;164(7):1202–1210.
- Lembo A et al. The colonic biological clock and predictability of time of bowel movements during treatment with a vibrating capsule (Vibrant®) in patients with severe chronic idiopathic constipation. Oral abstract presentation, DDW, May 2023.
- National Institute of Diabetes and Digestive and Kidney Diseases: Symptoms and Causes of Constipation; Eating, Diet, and Nutrition for Constipation; Definition and Facts for Constipation.
- Bassotti G et al. Chronic Idiopathic Constipation in Adults: A Review on Current Guidelines and Emerging Treatment Options. Clin Exp Gastroenterol. 2021;14:413–428.
- Quigley EMM, Horn J, Kissous-Hunt M, Crozier RA, Harris LA. Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with IBS-C (BURDEN IBS-C). Adv Ther. 2018;35(7):967–980.
- Rao SSC et al. Real-World Evidence of the Long-Term Clinical Utility of a Vibrating Capsule in the Management of Chronic Idiopathic Constipation. Clin Transl Gastroenterol. 2025.